Account
Watchlists
Bookmarks
Pricing
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
No. of Analysts
1Y Price Target
Q3 EPS Estimate
Q3 Revenue Estimate
Price, EPS and Revenue Projections
Strong Buy
6
Buy
5
Hold
1
Sell
0
Strong Sell
0
updated on
Dec 03, 2025
Bearish
4
Neutral
4
Bullish
6
Bearish
36
Neutral
4
Bullish
6
Bearish
32
Neutral
0
Bullish
0
Get In-depth insights on EPS and Revenue forecasts
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Market Cap
₹ 59,278 Cr
P/E
39.28
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
27900.00 | 59,278 Cr | 39.28 | 14.78 | 1.70 | 37.62 | 48.38 | 26.50 | |
2575.00 | 43,623 Cr | 45.76 | 25.54 | 2.10 | 55.94 | 74.64 | 26.06 | |
5034.00 | 22,933 Cr | 32.45 | 5.96 | 3.29 | 18.36 | 24.12 | 18.22 | |
9137.50 | 22,811 Cr | 98.68 | 28.55 | 0.35 | 28.93 | 37.48 | 12.33 | |
4570.00 | 10,559 Cr | 49.14 | 41.08 | 1.20 | 77.82 | 92.58 | 51.64 | |
4204.00 | 9,666 Cr | 25.45 | 11.23 | 2.78 | 42.11 | 52.41 | 25.64 | |
5663.25 | 9,422 Cr | 30.71 | 15.20 | 2.20 | 49.51 | 65.17 | 34.30 |
Abbott India Ltd is a leading multinational pharmaceutical company with a manufacturing facility in Goa and various third-party manufacturers across India.
It operates in therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health, offering a diverse product portfolio.
The company has historic roots dating back to 1944, with multiple name changes reflecting its evolving business focus and strategic mergers.
Abbott India has launched numerous products across therapy segments, indicating significant portfolio expansion and innovation, particularly in gastrointestinal and women's health.
The company leverages strategic partnerships and advanced medical research to drive growth and maintain its strong market position in India.
Pharmaceuticals
Pharmaceuticals - Multinational
59,278 Cr
Low Risk
39.3
41.4
3.4
14.8
35,921.55
25,260.20
Sales CAGR
1Y
14.52%
3Y
9.26%
5Y
9.38%
10Y
10.33%
Profit CAGR
1Y
16.35%
3Y
20.99%
5Y
18.99%
10Y
20.96%
ROE
TTM
37.62%
3Y
32.06%
5Y
30.55%
10Y
27.84%
ROCE
TTM
48.38%
3Y
41.15%
5Y
39.12%
10Y
36.85%
Performance
STEADY PERFORMER
Valuation
REASONABLE
Growth
STABLE
Profitability
HIGH MARGIN
Technicals
Bearish
Risk
LOW RISK
